The purpose of this study is to determine whether: A)the continuous infusion ultra-low dose of terlipressin (1.3 micrograms/kg/h) is able to stabilize hemodynamic in patients with septic shock, reducing the risk of adverse effects related to the bolus dose.B)the continuous infusion ultra-low dose of terlipressin may be use in lieu of vasopressin.
Forty-five septic shock patients requiring vasopressor support to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation were enrolled in the study. Patients were randomly allocated to be treated with either a) a continuous terlipressin infusion (1.3 µg•kg-1), b) vasopressin (0.03 U•min-1), or c) titrated norepinephrine (control; each n = 15). In both the terlipressin and vasopressin group, norepinephrine was additionally administered to achieve a mean arterial pressure (MAP) between 65 and 75 mmHg, if necessary. Data from right heart catheterization, thermo-dye dilution catheter, gastric tonometry as well as data from organ function, cytokines concentrations, were obtained at baseline and after 12, 24, 36 and 48 hours.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
45
continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
titrated norepinephrine over a period of 48 hrs
Department of Anesthesiology and Intensive care of the University of Rome "La Sapienza"
Rome, Viale Del Policlinico 155, Italy
Systemic and regional hemodynamics
Time frame: during the first 48 hours from the onset of septic shock
Markers of inflammation,organ functions,adverse effects.
Time frame: during the first 48 hours from the onset of septic shock
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.